From cells to therapeutics, organs and sustainable source of food
We convert cells from humans and animals into a competent, functional skeletal muscle tissue to model diseases, develop diverse therapeutic modalities, regenerate aged muscle, grow organs and make synthetic meat.
We use healthy or affected skeletal muscle progenitors cells to model neuromuscular diseases and to discover diverse therapeutics.
Our proprietary skeletal muscle differentiation platform reliably and reproducibly converts pluripotent or embryonic stem cells into satellite cells and myoblasts with high regenerative potential. This process does not require genetic intervention or cell sorting. It yields a homogeneous and physiologically competent population of cells and/or cultures immediately suitable for screening and advanced drug discovery.
Accelerated discovery-to-clinic timelines for clinical development of diverse therapies to treat skeletal muscle.
Facioscapulohumeral Dystrophy (FSHD, TYPES I/II): GBC0905
Satellite Cells for Muscle Regeneration
Spinal Muscular Atrophy (Skeletal Muscle)
Kennedy’s Disease (SBMA)
Mini-muscles: collaborative efforts
18 years experience in cell/stem cell biology focused on laboratory applications, scale up, assay development, production and automation; experienced in clinical regulatory and biosafety disciplines; Director of Operations.
25 years of industry experience in developing and commercializing innovative therapies; Business Development, currently the CEO of Genea Biomedx, Non-Executive Director to support Myocea’s fundraising activities.
PhD, Founder and Chairman of the Board
Over two decades of drug discovery and development expertise in pharma and biotech companies including Amgen, ImClone/Lilly, deCODE, Genea Biocells; diverse modalities in mid/late stages of clinical developments to treat oncology, CNS, metabolic and neuromuscular disorders with specific emphasis on rare diseases; over 170 peer-reviewed publications and over 60 granted patents and patent applications.
PhD; over 45 years of experience in molecular diagnostics, founder and board of director of Pangenia Inc.
25 years of industry experience in developing and commercializing innovative therapies; currently the CEO of Genea Biomedx
Dr. Emerson is a key opinion leader in the field of muscular disorders. His research has focused on defining transcriptional networks and signaling pathways that control the specification and differentiation of skeletal muscle progenitors. Current studies utilize iPSC and xenograft technologies to model the molecular pathology of facioscapulohumeral (FSHD) and LGMD2i muscular dystrophies.
Dr. Lawrence Hayward is a physician-scientist providing care since 2000 for patients in the UMMS MDA Neuromuscular Clinic. Dr. Hayward serves as Co-Director of the multidisciplinary FSH Muscular Dystrophy Clinic. His research group focuses on defining molecular mechanisms that cause neuromuscular diseases including ALS, FSHD, and hyperkalemic periodic paralysis in order to design effective therapeutics for these conditions.
Dr. Lam is board certified in both Internal Medicine and Medical Oncology. He was on the faculty of the University of Arizona until June 1999, when he joined UC Davis School of Medicine as the Division Chief of Hematology/Oncology, Beginning April 1, 2010, he became the Chair of Department of Biochemistry and Molecular Medicine. He is both a practicing medical oncologist and a laboratory investigator.
Want to say hello? Want to know more about us? Give us a call or drop us an email and we will get back to you as soon as we can.
© 2022 MYOCEA - All Rights Reserved - Terms of Service